J Korean Med Sci.  2024 Jan;39(2):e26. 10.3346/jkms.2024.39.e26.

Case 18: A 66-Year-Old Woman With Dizziness and Left Side Weakness

• Shin K
• Mun HW
• Kim S
• Park GE
• Song JH
• Lee J

• KMID: 2550801
• DOI: http://doi.org/10.3346/jkms.2024.39.e26

Figure

• 

  Fig. 1 Baseline and follow-up brain magnetic resonance imaging of the patient. (A-C) Axial T2 weighted image of brain MRI before trastuzumab-deruxtecan. The perilesional edema seen around the multiple lesions appears as high signal intensity. (D-L) Axial contrast-enhanced T1 weighted images of brain MRI. (D-F) Multiple, variably sized nodular and rim-enhancing lesions are seen throughout the brain before treatment. A tiny nodular enhancing lesion is observed in the complex of the seventh and eighth cranial nerves on the left (F, arrow). (G-I) After four cycles of trastuzumab-deruxtecan, multiple variable lesions in the brain have significantly decreased. (J-L) After eight cycles of trastuzumab-deruxtecan, most of the brain lesions have regressed, showing a near-complete response.MRI = magnetic resonance imaging.

• 

  Fig. 2 Baseline and follow-up thoracic computed tomography of the patient. (A, arrow) Enhanced neck CT shows diffuse low-attenuating infiltration in the thyroid gland, suggesting thyroid metastases. (B, arrow) Enhanced chest CT reveals an irregular nodular lesion in the right middle lobe, suggesting lung metastasis. (C, D) After eight cycles of trastuzumab-deruxtecan, most of the lesions have regressed, showing a near-complete response.CT = computed tomography.

Reference

1. Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021; 32(11):1332–1347. PMID: 34364998.

2. Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol. 2022; 40(23):2636–2655. PMID: 35640075.

3. Schiff D, Messersmith H, Brastianos PK, Brown PD, Burri S, Dunn IF, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline. J Clin Oncol. 2022; 40(20):2271–2276. PMID: 35561283.

4. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017; 3(8):1069–1077. PMID: 28301662.

5. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113(10):2638–2645. PMID: 18833576.

6. Pieńkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol. 2010; 21(5):917–924. PMID: 19717536.

7. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14(1):64–71. PMID: 23122784.

8. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019; 37(13):1081–1089. PMID: 30860945.

9. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023; 9(2):197–205. PMID: 36454580.

10. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020; 20(1):26–41. PMID: 31601988.

11. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87(5):586–592. PMID: 20357763.

12. Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, et al. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015; 5(1):8. PMID: 25853014.

13. Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020; 31(10):1350–1358. PMID: 32634611.

14. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023; 22(2):101–126. PMID: 36344672.

15. Hurvitz S, Modi S, Li W, Park Y, Chung W, Kim S, et al. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03. Ann Oncol. 2023; 34:S335–S336.

16. Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022; 28(9):1840–1847. PMID: 35941372.

17. Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023; 25(1):157–166. PMID: 35639825.